AbbVie Shares Slip 2.4% as Q2 Immunology Sales Set to Offset Humira Decline
ABBV•AbbVie shares dropped 2.42% on July 6 during a sector-wide pullback after Eli Lilly flagged excess demand. Ahead of its July 31 Q2 report, rising Skyrizi and Rinvoq immunology sales are expected to partially offset Humira’s revenue decline.
1. July 6 Share Performance
AbbVie shares tumbled 2.42% on July 6, underperforming broader healthcare peers after investors reacted to reports of excess demand in the biotech sector. The pullback followed commentary from a leading competitor, prompting a broad sell-off in large-cap pharma names.
2. Immunology Franchise Growth
AbbVie’s immunology division has gained momentum this quarter, with Skyrizi and Rinvoq driving double-digit sales growth as physicians continue to adopt the newer therapies. Management plans to highlight this segment’s expansion as a key offset to legacy product pressures.
3. Humira Revenue Challenges
Humira faces ongoing patent expirations and biosimilar competition, leading to a notable year-over-year sales decline in Q2. Analysts expect immunology revenues will soften the impact of Humira’s drop when AbbVie reports earnings on July 31.
